Mesoblast (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for remestemcel-L in the treatment of acute respiratory distress syndrome (ARDS) due to Covid-19 infection..
Fast Track designation is granted if a therapy demonstrates the potential to address unmet medical needs for a serious or life-threatening disease.
ARDS is the primary cause of death in patients with Covid-19.
Shares in Mesoblast (ASX:MSB) are trading 0.3 per cent lower at $20.23.
16 Nov 2023 - A snapshot of the stocks on the move, featuring Galan Lithium (ASX:GLN), Vulcan Energy Resources (ASX:VUL), ABx (ASX:ABX) and Bryah Resources (ASX:BYH).
26 Feb 2021 - Prime Media’s (ASX:PRT) interim financial results for the half-year ended 31 December 2020 show total revenue edged 1 per cent higher year on year to $91.7 million.
24 Jun 2020 - Village Roadshow’s (ASX:VRL) Gold Coast theme parks Warner Bros. Movie World, Sea World, Wet'n'Wild and Paradise Country have had their Covid Safe plans approved by the Queensland Government and are able to reopen under those plans at up to 50 per cent capacity.
23 Sep 2020 - Installment payments platform, Sezzle, (ASX:SZL) is pleased to announce its business partnership with Ally Lending, the B2B2C lending arm of Ally Bank, the banking subsidiary of Ally Financial (NYSE:ALLY).
